Cite
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients.
MLA
Zhu, Tong, et al. “Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients.” Clinical Pharmacology in Drug Development, vol. 5, no. 5, Sept. 2016, pp. 408–25. EBSCOhost, https://doi.org/10.1002/cpdd.251.
APA
Zhu, T., Keirns, J., Howieson, C., Kaibara, A., Goldwater, R., Kivitz, A. J., Chindalore, V., Cohen, S., Santos, V., Akinlade, B., Kernstock, R., Delgado, H. L., Blahunka, P. C., Karrer, E. E., Garg, J. P., Samberg, N., & Zeiher, B. G. (2016). Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients. Clinical Pharmacology in Drug Development, 5(5), 408–425. https://doi.org/10.1002/cpdd.251
Chicago
Zhu, Tong, James Keirns, Corrie Howieson, Atsunori Kaibara, Ronald Goldwater, Alan J. Kivitz, Vishala Chindalore, et al. 2016. “Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients.” Clinical Pharmacology in Drug Development 5 (5): 408–25. doi:10.1002/cpdd.251.